Investigation of pathogen resistance in Chinese cancer patients based on bacterial resistance surveillance in 23 provinces, 2016–2023
Authors:
Open Access
- 16 July 2026
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 17, 1848531
Abstract
Background: Infection is a common and often fatal complication in cancer patients. Notably, cancer patients account for up to 21% of all sepsis cases. Furthermore, sepsis is present in 30% of all deaths among those hospitalized with cancer. However, comprehensive antimicrobial resistance (AMR) surveillance data specific to this population are lacking. This gap hinders the effectiveness of antimicrobial stewardship programs (ASPs). Methods: We investigated bacterial distribution and AMR patterns in Chinese cancer patients to inform empirical therapy and ASPs. This multicenter retrospective study collected hospital-wide clinical isolates and drug-susceptibility data from 23 cancer centers during 2016–2023. All procedures followed standardized methods in accordance with national surveillance protocols and Clinical and Laboratory Standards Institute guidelines. Data were subjected to dual validation using WHONET and a domestically developed big-data system. Results: Gram-negative 75.4% (270,609), Gram-positive 24.6% (88,177) of 358,786 isolates from cancer patients in these oncology centers. Predominant Gram-negative species were Klebsiella pneumoniae , Escherichia coli , Pseudomonas aeruginosa , Acinetobacter baumannii , and Enterobacter cloacae . Escherichia coli exhibited low imipenem resistance (0.9–1.5%) with a recent increase (2021–2023: APC = 16.57%, p < 0.001). Klebsiella pneumoniae showed stable imipenem resistance (1.6–1.9%) but increasing meropenem resistance (0.4–1.6%). Pseudomonas aeruginosa imipenem resistance declined (12.5–7.9%), while meropenem resistance remained stable (7.0–5.2%); while Acinetobacter baumannii carbapenem resistance increased substantially (imipenem: 9.6–18.4%; meropenem: 4.7–18.8%). Leading Gram-positive organisms were Staphylococcus epidermidis , Staphylococcus aureus , Enterococcus faecium , Enterococcus faecalis , and Staphylococcus haemolyticus . Methicillin-resistant Staphylococcus aureus (MRSA) resistance declined over five years, with no resistance to linezolid, vancomycin, or teicoplanin. Enterococcus spp. gradually developed resistance to last-resort antibiotics. Conclusion: Carbapenem resistance among common Gram-negatives in cancer patients was below national averages. MRSA and enterococcal resistance were also below national levels. These findings underscore the unique resistance epidemiology in oncology, supporting tailored guidelines and dedicated surveillance.Keywords
Funding Information
- Anticancer Fund
This publication has 25 references indexed in Scilit:
- The GLOBOCAN 2022 cancer estimates: Data sources, methods, and a snapshot of the cancer burden worldwideInternational Journal of Cancer, 2024
- Global Disparities of Cancer and Its Projected Burden in 2050JAMA Network Open, 2024
- Cancer incidence and mortality in China, 2022Journal of the National Cancer Center, 2024
- Prophylactic antibiotics for preventing gram-positive infections associated with long-term central venous catheters in adults and children receiving treatment for cancerCochrane Database of Systematic Reviews, 2021
- From the soil to the clinic: the impact of microbial secondary metabolites on antibiotic tolerance and resistanceNature Reviews Microbiology, 2021
- The Lancet Infectious Diseases Commission on antimicrobial resistance: 6 years laterThe Lancet Infectious Diseases, 2020
- Specific gut microbiota changes heralding bloodstream infection and neutropenic fever during intensive chemotherapyLeukemia, 2019
- Rationalizing antimicrobial therapy in the ICU: a narrative reviewIntensive Care Medicine, 2019
- Prophylactic antibiotics for preventing Gram positive infections associated with long-term central venous catheters in oncology patientsCochrane Database of Systematic Reviews, 2013
- Intestinal Domination and the Risk of Bacteremia in Patients Undergoing Allogeneic Hematopoietic Stem Cell TransplantationClinical Infectious Diseases, 2012